Molecular insights into Crimean-Congo hemorrhagic fever virus

M Zivcec, FEM Scholte, CF Spiropoulou, JR Spengler… - Viruses, 2016 - mdpi.com
Crimean-Congo hemorrhagic fever virus (CCHFV) is a tick-borne pathogen that causes high
morbidity and mortality. Efficacy of vaccines and antivirals to treat human CCHFV infections …

Neglected filoviruses

R Burk, L Bollinger, JC Johnson, J Wada… - FEMS microbiology …, 2016 - academic.oup.com
Eight viruses are currently assigned to the family Filoviridae. Marburg virus, Sudan virus
and, in particular, Ebola virus have received the most attention both by researchers and the …

[HTML][HTML] Systematic analysis of monoclonal antibodies against Ebola virus GP defines features that contribute to protection

EO Saphire, SL Schendel, ML Fusco, K Gangavarapu… - Cell, 2018 - cell.com
Antibodies are promising post-exposure therapies against emerging viruses, but which
antibody features and in vitro assays best forecast protection are unclear. Our international …

[HTML][HTML] Longitudinal analysis of the human B cell response to Ebola virus infection

CW Davis, KJL Jackson, AK McElroy, P Halfmann… - Cell, 2019 - cell.com
Ebola virus (EBOV) remains a public health threat. We performed a longitudinal study of B
cell responses to EBOV in four survivors of the 2014 West African outbreak. Infection …

Cross-reactive and potent neutralizing antibody responses in human survivors of natural ebolavirus infection

AI Flyak, X Shen, CD Murin, HL Turner, JA David… - Cell, 2016 - cell.com
Recent studies have suggested that antibody-mediated protection against the Ebolaviruses
may be achievable, but little is known about whether or not antibodies can confer cross …

Non-neutralizing antibodies from a Marburg infection survivor mediate protection by Fc-effector functions and by enhancing efficacy of other antibodies

PA Ilinykh, K Huang, RI Santos, P Gilchuk, BM Gunn… - Cell host & …, 2020 - cell.com
Marburg virus (MARV) and Ebola virus (EBOV) belong to the family Filoviridae. MARV
causes severe disease in humans with high fatality. We previously isolated a large panel of …

The marburgvirus-neutralizing human monoclonal antibody MR191 targets a conserved site to block virus receptor binding

LB King, ML Fusco, AI Flyak, PA Ilinykh, K Huang… - Cell host & …, 2018 - cell.com
Since their first identification 50 years ago, marburgviruses have emerged several times,
with 83%–90% lethality in the largest outbreaks. Although no vaccines or therapeutics are …

A roadmap for the molecular farming of viral glycoprotein vaccines: engineering glycosylation and glycosylation-directed folding

E Margolin, M Crispin, A Meyers, R Chapman… - Frontiers in Plant …, 2020 - frontiersin.org
Immunization with recombinant glycoprotein-based vaccines is a promising approach to
induce protective immunity against viruses. However, the complex biosynthetic maturation …

Post-exposure immunotherapy for two ebolaviruses and Marburg virus in nonhuman primates

JM Brannan, S He, KA Howell, LI Prugar, W Zhu… - Nature …, 2019 - nature.com
Abstract The 2013–2016 Ebola virus (EBOV) disease epidemic demonstrated the grave
consequences of filovirus epidemics in the absence of effective therapeutics. Besides EBOV …

Single-component multilayered self-assembling nanoparticles presenting rationally designed glycoprotein trimers as Ebola virus vaccines

L He, A Chaudhary, X Lin, C Sou, T Alkutkar… - Nature …, 2021 - nature.com
Ebola virus (EBOV) glycoprotein (GP) can be recognized by neutralizing antibodies (NAbs)
and is the main target for vaccine design. Here, we first investigate the contribution of the …